The mTTR mut promoter with the mentioned mutation was subsequently used for factor VIII expression in AAV-mediated gene therapies SPK-8011 and NGGT003 for hemophilia A without an enhancer region due to AAV vector capacity limitations. Here, MT-TR is linked to hemophilia A.